Normal.dot

1 Name of Determination

(1) This instrument is the National Health (April 2023 Price Reductions) (Exercise of Ministerial discretion) Determination (No.2) 2023.

(2) This instrument may also be cited as PB 31 of 2023.

2 Commencement

(1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

Commencement information
Column 1	Column 2	Column 3
Provisions	Commencement	Date/Details
1. The whole of this instrument	The day this instrument is registered.

Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

(2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3 Definition

Note: A number of expressions used in this instrument are defined in Part VII the Act.

In this instrument:

Act means the National Health Act 1953.

catch-up price reduction day has the same meaning as in subsection 99ACN(6) of the Act.

4 Authority

This instrument is made under subsection 99ACF(3) of the Act.

5 Brand of pharmaceutical item (combination item) subject to a lower price reduction than would otherwise apply

I determine, under paragraph 99ACF(3)(b) of the Act, that the approved ex-manufacturer price, and each of the claimed prices (if applicable) of a brand of pharmaceutical item (combination item) specified in column 2 of an item in the table in Schedule 1 is reduced under a provision mentioned in item 8 of the table in subsection 99ACF(1) of the Act, as appropriate, in relation to the catch-up price reduction day by the percentage specified in column 3 of the table item.

6 Brand of pharmaceutical item not subject to a price reduction

I determine, under paragraph 99ACF(3)(a) of the Act, that the approved ex-manufacturer price, and each of the claimed prices (if applicable) of each brand of pharmaceutical item specified in column 2 as an item in the table in Schedule 2 is not reduced under a provision mentioned in item 8 of the table in subsection 99ACF(1) of the Act, as appropriate, in relation to the catch-up price reduction day.

7 Brand of pharmaceutical item subject to a lower price reduction than would otherwise apply

I determine, under paragraph 99ACF(3)(b) of the Act, that the approved ex-manufacturer price, and each of the claimed prices (if applicable) of a brand of pharmaceutical item specified in column 2 of an item in the table in Schedule 3 is reduced under a provision mentioned in item 8 of the table in subsection 99ACF(1) of the Act, as appropriate, in relation to the catch-up price reduction day by the percentage specified in column 3 of the table item.

Schedule 1— Brands of pharmaceutical items (combination items) with approved ex-manufacturer price reduced by a lower percentage than would otherwise apply

Column 1	Column 2				Column 3
Item	Brand of pharmaceutical item				% reduction
	Drug	Form	Manner of administration	Brand
1	Buprenorphine with naloxone	Film (soluble) 8 mg (as hydrochloride)-2 mg (as hydrochloride)	Sublingual	Suboxone Film 8/2	10%

Schedule 2— Brands of pharmaceutical items with approved ex-manufacturer price not reduced

Column 1	Column 2
Item	Brand of Pharmaceutical Item
	Drug	Form	Manner of administration	Brand(s)
1	Pancrelipase	Capsule (containing enteric coated microtablets) providing not less than 25,000 BP units of lipase activity (s19A)	Oral	Panzytrat 25 000 (Allergan)
2	Tenecteplase	Powder for injection 50 mg with solvent (s19A)	Injection	TNKase (Canada)

Schedule 3 — Brands of pharmaceutical items with approved ex-manufacturer price reduced by a lower percentage than would otherwise apply

Column 1	Column 2				Column 3
Item	Brand of pharmaceutical item				% reduction
	Drug	Form	Manner of administration	Brand
1	Buprenorphine	Injection (modified release) 8 mg in 0.16 mL pre-filled syringe	Injection	Buvidal Weekly	5%
2	Buprenorphine	Injection (modified release) 16 mg in 0.32 mL pre-filled syringe	Injection	Buvidal Weekly	5%
3	Buprenorphine	Injection (modified release) 24 mg in 0.48 mL pre-filled syringe	Injection	Buvidal Weekly	5%
4	Buprenorphine	Injection (modified release) 32 mg in 0.64 mL pre-filled syringe	Injection	Buvidal Weekly	5%
4	Buprenorphine	Injection (modified release) 64 mg in 0.18 mL pre-filled syringe	Injection	Buvidal Monthly	5%
5	Buprenorphine	Injection (modified release) 96 mg in 0.27 mL pre-filled syringe	Injection	Buvidal Monthly	5%
6	Buprenorphine	Injection (modified release) 128 mg in 0.36 mL pre-filled syringe	Injection	Buvidal Monthly	5%
7	Buprenorphine	Injection (modified release) 160 mg in 0.45 mL pre-filled syringe	Injection	Buvidal Monthly	5%
8	Buprenorphine	Injection (modified release) 100 mg in 0.5 mL pre-filled syringe	Injection	Sublocade	5%
9	Buprenorphine	Injection (modified release) 300 mg in 1.5 mL pre-filled syringe	Injection	Sublocade	5%
10	Buprenorphine	Tablet (sublingual) 2 mg (as hydrochloride)	Sublingual	Subutex	15%
11	Buprenorphine	Tablet (sublingual) 400 micrograms (as hydrochloride)	Sublingual	Subutex	14.89%
12	Buprenorphine	Tablet (sublingual) 8 mg (as hydrochloride)	Sublingual	Subutex	16.12%
13	Insulin aspart	Injection (human analogue) (fast acting) 100 units per mL, 10 mL vial	Injection	Fiasp	22.22%
14	Insulin aspart	Injections (human analogue) (fast acting), pre-filled pen, 100 units per mL, 3 mL, 5	Injection	Fiasp FlexTouch	22.22%